Skip to main content

Patient Square Capital Adds Adam Fliss As Founding Partner And General Counsel

Patient Square Capital has added Adam Fliss as a Founding Partner and General Counsel. Fliss will become the third Founding Partner of Patient Square, joining Jim Momtazee, Managing Partner, and Maria Walker, Founding Partner and Chief Financial Officer. Prior to Patient Square, Fliss was the General Counsel of TPG Capital, the private equity platform of alternative asset firm TPG. 

During his tenure at TPG, Fliss was involved in hundreds of private equity transactions across all aspects of health care and other sectors, including technology, software and digital media. He also was active in portfolio company value creation, government affairs, compliance and investor relations, and served as a senior leader in the larger TPG enterprise. Prior to TPG, he was an associate in the private equity group at Ropes & Gray. 

"The size and complexity of the health care industry creates a need for an investment firm focused exclusively on health care and capable of investing capital in significant scale," said Momtazee. "Adam's legal background and judgment, deep transactional and health care experience and entrepreneurial mindset will help us to build Patient Square Capital and partner with world-class companies and management teams. We anticipate adding additional Founding Partners with deep health care and transactional experience in the coming months."

"Jim is one of the most experienced and well-respected investors in health care," said Fliss. "From our first conversation we were aligned on the benefits of specialization and scale in an industry as large and complex as health care. I am honored to be joining Maria and him in building Patient Square Capital."

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.